A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab
Public ClinicalTrials.gov record NCT02203032. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Guselkumab for the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab
Study identification
- NCT ID
- NCT02203032
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Enrollment
- 872 participants
Conditions and interventions
Conditions
Interventions
- Guselkumab Drug
- Placebo for guselkumab Drug
- Placebo for ustekinumab Drug
- Ustekinumab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 99 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 6, 2014
- Primary completion
- Dec 24, 2015
- Completion
- May 23, 2016
- Last update posted
- Sep 11, 2017
2014 – 2016
United States locations
- U.S. sites
- 29
- U.S. states
- 17
- U.S. cities
- 29
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Birmingham | Alabama | — | — |
| Not listed | Bakersfield | California | — | — |
| Not listed | Los Angeles | California | — | — |
| Not listed | Santa Monica | California | — | — |
| Not listed | Coral Gables | Florida | — | — |
| Not listed | Ocala | Florida | — | — |
| Not listed | Alpharetta | Georgia | — | — |
| Not listed | Atlanta | Georgia | — | — |
| Not listed | Arlington Heights | Illinois | — | — |
| Not listed | Chicago | Illinois | — | — |
| Not listed | Skokie | Illinois | — | — |
| Not listed | Indianapolis | Indiana | — | — |
| Not listed | Plainfield | Indiana | — | — |
| Not listed | Louisville | Kentucky | — | — |
| Not listed | Boston | Massachusetts | — | — |
| Not listed | Troy | Michigan | — | — |
| Not listed | Buffalo | New York | — | — |
| Not listed | New York | New York | — | — |
| Not listed | Portland | Oregon | — | — |
| Not listed | Pittsburgh | Pennsylvania | — | — |
| Not listed | Johnston | Rhode Island | — | — |
| Not listed | Nashville | Tennessee | — | — |
| Not listed | Arlington | Texas | — | — |
| Not listed | Austin | Texas | — | — |
| Not listed | Dallas | Texas | — | — |
| Not listed | San Antonio | Texas | — | — |
| Not listed | Webster | Texas | — | — |
| Not listed | Norfolk | Virginia | — | — |
| Not listed | Spokane | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 56 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02203032, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 11, 2017 · Synced May 12, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02203032 live on ClinicalTrials.gov.